anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic hepatitis B virus (HBV) infection is a global public health problem affecting more than 250 million people at high risk of death from cirrhosis and liver cancer. The goal of therapy for patients with chronic hepatitis B (CHB) is to improve survival and quality of life by preventing disease progression to cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). This can be achieved by elimination of HBV or sustained suppression of viral replication with antiviral treatment. In recent years, accompanied by the growing prevalence of obesity, fatty liver disease is commonly observed in patients with CHB. The prevalence of the fatty liver disease is approximately 14-67% in Asian individuals with CHB, similar to Western countries. The coexistence of CHB and hepatic steatosis, particularly steatohepatitis, can aggravate liver damage and increase the risk of fibrosis. A recent histological study showed a significant association between steatohepatitis and advanced fibrosis in CHB patients.

Fatty liver disease has been shown to increase the risk of fibrosis progression in patients with CHB receiving antiviral treatment. According to a follow-up study of cirrhotic patients treated with tenofovir disoproxil fumarate for CHB, patients with possible concurrent NAFLD were less likely to have fibrosis regression despite viral suppression. Likewise, another prospective study showed that lower body mass index was independently associated with fibrosis regression in CHB patients who achieved undetectable HBV viral load during long-term nucleoside analogue therapy. Hence, monitoring the development of unfavorable outcomes is recommended in this population. However, there are limited data on the impact of concurrent fatty liver disease on clinical outcomes (e.g., cirrhotic complications, HCC, and death) during comprehensive treatment for CHB. Therefore, this longitudinal cohort study aimed to determine the effect of concurrent fatty liver disease on overall survival and liver-related complications among CHB patients receiving antiviral therapy to improve our understanding of the prognostic value of concurrent fatty liver disease in these patients.

METHODS The investigators conduct a retrospective analysis of a prospectively collected database of patients with chronic HBV infection who underwent a liver biopsy between 2002 and 2008 at the Faculty of Medicine Siriraj Hospital in Bangkok, Thailand. This cohort includes only patients who had at least moderate necroinflammation and/or liver fibrosis stage 2 or higher according to the METAVIR system and have been treated with antiviral agents. Patients will be excluded from analysis if they had co-infection with hepatitis C virus or human immunodeficiency virus; had the presence of alcohol dependence; had follow-up data less than six months in our clinic; had no available liver histology for review; had intermittent or persistent HBV DNA \>2000 IU/ml after stopping antiviral agents during follow-up.
Methods and node-enabled apparatus are described that involve use of node-enabled packaging material as part of a container for an item to be shipped. The method begins by forming at least a part of the container with the packaging material. Next, the method activates a node integrated as part of the packaging material. The node is operative to communicate with one or more network devices (such as an ID node, master node and/or server) in a wireless node network. The method then registers shipping information with a server in the wireless node network via a user access device operated by a shipping customer. The shipping information is related to the container and the node integrated as part of the packaging material of the container. The item to be shipped may be sealed within the container.
The gene for outer membrane protein P1 of Haemophilus influenzae b is expressed in E. coli. Methods for expression and demonstration of the immunogenicity of recombinant P1 and portions thereof are disclosed, along with an improved method for the purification of P1. The nucleotide sequence of the P1 gene and the derived amino acid sequence of the P1 protein of Haemonhilus influenzae type b are disclosed and the methods used to determine the same. Also disclosed are the methods used to clone and express the P1 gene as wall as the purification protocol for the P1 gene products (recombinant P1 and P1 fusion proteins). Fourteen peptides are synthesized corresponding to specific sequences of the mature P1 protein. The use of the P1 protein as n immunogens for immunization against the disease caused by Haemophilus influenzae type b and the use of the protein as a carrier for conjugation with an oligosaccharide derived from Haemophilus to generate a potentially efficacious vaccine against the disease, are described. Also disclosed is the use of P1 peptide-conjugates as immunizing agents to elicit anti-Haemophilus influenzae type b antibodies.
Implantable medical devices (IMDs) having anti-infective properties are described. Anti-infective agents are disposed in, on, or about at least a portion of a surface of the medical device. The anti-infective agents are disposed in or on a vehicle, which may be in the form of a coating layer or covering. The vehicle may be biodegradable so that, over time, the anti-infective agent is removed from a tissue location into which the device is implanted, reducing the likelihood that microorganisms resistant to the anti-infective agent will develop. IMDs having an anti-infective agent and an anti-activity agent disposed therein, thereabout, or thereon are also described. The anti-activity agent interferes with the activity of the anti-infective agent, may be released from a surface at the IMD at a time when activity of the anti-infective agent is no longer desired, and may reduce the likelihood that microorganisms resistant to the anti-infective agent will develop.
BACKGROUND: Acute gastroenteritis is one of the major causes of morbidity and mortality in young children worldwide. Among these, rotavirus, norovirus, and adenovirus have been reported as the primary viral pathogens associated with the disease. Rapid diagnosis of viral pathogens is crucial when diarrhea outbreaks occur to ensure the timely administration of appropriate treatment and control measures.
METHODS: We evaluated three immunochromatographic test kits designed for the detection of norovirus, rotavirus, and adenovirus in 71 stool specimens collected from children with diarrhea who visited clinics in Japan. The first kit is a triplex immunochromatographic test kit designed for simultaneous detections of norovirus, rotavirus, and adenovirus on a single strip (this kit was referred to as IC-A). The other two immunochromatographic test kits are a dual detection kit for rotavirus and adenovirus, and a single detection kit for norovirus (IC-B). The RT-PCR/PCR was used as the gold standard method.
RESULTS: The results revealed that both IC-A and IC-B kits exhibited the same level of sensitivity of detection for rotavirus (72.7%) and adenovirus (22.7%), although the detection rate was lower than that of the RT-PCR/PCR method. However, there was a slight difference in the sensitivity of detection for norovirus between IC-A and IC-B, at 86.7% and 93.3%, respectively. The sensitivity of detection for adenovirus of both kits was relatively lower than those of RT-PCR method. This could be due to low viral load of adenovirus in clinical specimens below the detection limit of IC-A and IC-B kits. However, both immunochromatographic test kits (IC-A and IC-B) exhibited 100% specificity for norovirus, rotavirus, and adenovirus.
CONCLUSIONS: The triplex immunochromatographic test kit (IC-A) designed for simultaneous detection of norovirus, rotavirus, and adenovirus has been proved to be more practical and convenient than the use of single or dual detection kits with more or less the same sensitivity and specificity of detections.
BACKGROUND: Intermittent theta burst stimulation (iTBS) is a newer form of Repetitive Transcranial Magnetic Stimulation (rTMS) for depression. However, its efficacy and safety in adolescents and young adults with major depressive disorder (AYA-MDD) have not been well studied, especially when applied with a strategy that combines neuronavigation targeting and accelerated iTBS.
METHODS: In this study, ninety patients were randomly assigned to twice-daily (two 600-pulse sessions spaced out by 10 min, n = 31), once-daily (one 600-pulse session, n = 29) or sham iTBS (no pulses, n = 30) groups for 10 treatment days. The primary outcome measure was the change in depression scores on the Hamilton Rating Scale for Depression (HAMD-17). Other clinical symptoms, such as anxiety, were also evaluated.
RESULTS: Linear mixed model analysis found that scores on the HAMD-17 and its factors improved in all three groups, but these improvements did not significantly differ among groups. Other clinical symptoms such as anxiety also improved. Response and remission rates were relatively low and did not differ among groups at any time point. The most common adverse event was headache, and the proportion of participants who reported headache in the twice-daily and once-daily groups was significantly higher than that in the sham group.
CONCLUSIONS: The current results indicated that twice-daily and once-daily iTBS under neuronavigation are safe and well tolerated in AYA-MDD, but the overall efficacy was not superior to that of sham treatment. We speculated several possible reasons such as the high placebo response of the young population, inadequate iTBS pulses and so on.
<P>PROBLEM TO BE SOLVED: To provide rigid capsules intended for coloration of their own for preventing misuse and production convenience(securing discrimination).  <P>SOLUTION: The rigid capsules having specks-free neat color tone and gloss are obtained by using a condensed phosphate salt in making a coloration with a natural coloring matter (especially a flavonoid-one). The cause of developing above-mentioned specks is that, when used a flavonoid-based coloring matter, it is bound to extremely minute amounts of metal ions inevitably contaminated from raw materials and/or production process system to effect forming colored and hard-to-dissolve salt(s). By adding the condensed phosphate salt, such hard-to-dissolve salt formation can be prevented. The rigid capsules can be used for pharmaceuticals or foods, being very useful.  <P>COPYRIGHT: (C)2007,JPO&INPIT
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to medicine. What is described is a preparation for percutaneous absorption containing a medical composition for percutaneous absorption in which an active component selected from morphine and its salts, is mixed in such amount which matches with saturation solubility or more, with an excipients keeping an active ingredient, having fluidity at temperature approximately equal to human skin surface temperature, and at least a portion of the active ingredient is found as crystals. The preparation is applied to an intact skin of a back of a white rabbit cut by electric shaver for 72 o'clock; an available dose of the active component in one dose of the preparation makes 10 mg to 400 mg of morphine at the morphine base, and the plasma concentration of the active ingredient 24 hours and 48 hours after the preparation application in the conditions specified above makes in each case at least 40 ng/ml at the morphine base. ^ EFFECT: preparation for percutaneous absorption is capable to support blood morphine concentration for a log time at an effective level for at least 48 hours. ^ 35 cl, 2 dwg, 6 tbl, 16 ex
Sepsis and Septic Shock are common and highly morbid clinical conditions without any specific therapy aside from antibiotics. A recent quasi-experimental study (Marik et. al., PMID 27940189) demonstrated a remarkable benefit when the combination of Ascorbic Acid (Vitamin C), Corticosteroids, and Thiamine (Vitamin B1) were given to patients with sepsis. In particular, patients who received this combination of medications required a shorter amount of time on vasopressors, suffered less organ failure, and had improved mortality. Vitamin C has long been suggested for treatment of patients with severe infection as it exerts significant anti-oxidant effects and reduces endothelial permeability. Corticosteroids, a mainstay of therapy for refractory shock in sepsis, have also been shown to enhance the beneficial cellular effects of vitamin C. Finally, thiamine has been shown to be an effective mitochondrial resuscitator in sepsis, especially for the \~30% of septic shock patients who present with thiamine deficiency (Donnino et. al, PMID 26771781).

In this study, we aim to reproduce the findings of Marik et. al. using a more rigorous study design (i.e. a blinded, randomized clinical trial) and focus on the important clinical outcomes of organ failure and death.
The two rotors comprise discs (12) with fan blades attached on one side. The fan blades are arranged in concentric rings received by corresponding channels in the opposing rotor disc in order to prevent passage of material under the blades. The machine consists of a casing with two rotors, each of which comprises several rings that engage inside one another and are driven in counter-rotation with an identical angular velocity. The rings are separately controlled and carry a number of fan blades on both of the ring walls, acting as a collision barrier for the material being milled and micronized. Centrifugal force carries the material from the inner ring towards the outer ring. Independent claims are also included for (a) the use of micronized zeolite as a drug for treating cancer, metabolism, heart and blood circulation complaints, multiple sclerosis and rheumatism, as a drug for dermatological applications, as a cosmetic, as an additive for bakery and confectionery products, as a filter material, as a filter additive for filter cigarettes, and as an additive for tile making, (b) the use of micronized minerals, especially calcites, as plant protection agents, (c) the use of micronized minerals, especially calcites, dolomites and carbonates, as fertilizers and/or yield increasing agents in agriculture, (d) the use of micronized minerals as odor reducing agents, and (e) the use of micronized clay components for reducing the sintering temperature during sintering processes used in the ceramic or glass industry.
BACKGROUND: Impaired cerebrovascular reactivity (CVR) has been correlated with recurrent ischemic stroke. However, for clinical purposes, most CVR techniques are rather complex, time-consuming, and lack validation for quantitative measurements. The recent adaptation of a standardized hypercapnic stimulus in combination with a blood-oxygenation-level-dependent (BOLD) magnetic resonance imaging signal as a surrogate for cerebral blood flow offers a potential universally comparable CVR assessment. We investigated the association between impaired BOLD-CVR and risk for recurrent ischemic events.
METHODS: We conducted a retrospective analysis of patients with symptomatic cerebrovascular large vessel disease who had undergone a prospective hypercapnic-challenged BOLD-CVR protocol at a single tertiary stroke referral center between June 2014 and April 2020. These patients were followed up for recurrent acute ischemic events for up to 3 years. BOLD-CVR (%BOLD signal change per mm Hg CO2) was calculated on a voxel-by-voxel basis. Impaired BOLD-CVR of the affected (ipsilateral to the vascular pathology) hemisphere was defined as an average BOLD-CVR, falling 2 SD below the mean BOLD-CVR of the right hemisphere in a healthy age-matched reference cohort (n=20). Using a multivariate Cox proportional hazards model, the association between impaired BOLD-CVR and ischemic stroke recurrence was assessed and Kaplan-Meier survival curves to visualize the acute ischemic stroke event rate.
RESULTS: Of 130 eligible patients, 28 experienced recurrent strokes (median, 85 days, interquartile range, 5-166 days). Risk factors associated with an increased recurrent stroke rate included impaired BOLD-CVR, a history of atrial fibrillation, and heart insufficiency. After adjusting for sex, age group, and atrial fibrillation, impaired BOLD-CVR exhibited a hazard ratio of 10.73 (95% CI, 4.14-27.81; P<0.001) for recurrent ischemic stroke.
CONCLUSIONS: Among patients with symptomatic cerebrovascular large vessel disease, those exhibiting impaired BOLD-CVR in the affected hemisphere had a 10.7-fold higher risk of recurrent ischemic stroke events compared with individuals with nonimpaired BOLD-CVR.
Anemia is sometimes seen in patients receiving NSAIDs. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including Flector Patch, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia.

NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Carefully monitor patients receiving Flector Patch who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants.
PROBLEM TO BE SOLVED: To produce a surfactant that is excellent in safety as well as excellent in the properties inherently possessed by a surfactant such as foaming properties, detergency or the like by using a compound of a structure obtained by adding a 1,2-epoxyalkane to a nitrogen atom of a hydroxamide in which a tertiary amino group is made ampholytic. SOLUTION: A compound of formula I is used. In the formula, R1 represents a group derived from a fatty acid; and X represents R3COO or R3SO3 (wherein R3 is a group derived from a monohalogenated sulfonate). Usually, the compound is produced by allowing a monohalogenated carboxylate or a monohalogenated sulfonate to react with a tertiary amino compound produced by addition reaction of a 1,2-epoxyalkane to a hydroxamide prepared by reacting a fatty acid with a hydroxy amine to make a tertiary amino group ampholytic. As a fatty acid, a 8-20C fatty acid, particularly one originating from a vegetable source, is preferable. As a hydroxy amine, a compound of formula II is preferable, and more preferable is one of formula II wherein n=2 to 3; and m=2 to 3.
The endoplasmic reticulum (ER) regulates protein folding and maintains proteostasis in cells. We observed that the ER transcriptome is impaired during chronic reductive stress (RS) in cardiomyocytes. Here, we hypothesized that a prolonged moderate treadmill exercise mitigates the RS-induced ER dysfunction and cardiac remodeling in cardiac-specific constitutively active Nrf2 mice (CaNrf2-TG). RNA sequencing showed notable alterations in the ER transcriptome of TG hearts at 4, 12, and 24 weeks (16, 28, and 35 genes, respectively). Notably, the downregulation of ER genes was significant at 12 weeks, and further pronounced at 24 weeks, at which the cardiac pathology is evident. We also observed increased levels of ubiquitinated proteins in CaNrf2-TG hearts across all ages, along with VCP, a marker of ERAD function, at 24 weeks. These findings indicate that constitutive Nrf2 activation and RS impair protein-folding activity and augments ERAD function over time. Exercise intervention for 20 weeks (beginning at 6 weeks of age), reduced cardiomyocyte hypertrophy (from 448 μm2 to 280 μm2) in TG mice, through adaptive remodeling, and preserved the cardiac function. However, while exercise did not influence antioxidants or ER stress protein levels, it significantly improved ERAD function and autophagy flux (LC-I to LC-II) in the TG-EXE hearts. Collectively, our findings underscore the prophylactic potential of exercise in mitigating RS-associated pathology, highlighting its essential role in maintaining cellular proteostasis through ER-independent mechanisms.
PURPOSE:To provide the titled complex capable of imparting antithrombogenic property to the necessary part in living body without deteriorating the function of the body, by bonding heparin with glycidyl trialkyl ammonium halide through ionic bond. CONSTITUTION:The objective novel complex is composed of heparin and glycidyl trialkyl ammonium halide (e.g. glycidyl trimethyl ammonium chloride) bonded together through ionic bond. An antithrombogenetic material or an anticoagulant is indispensable for the remedy of circulatory diseases. Heparin is being used singly for the purpose, however, the agent is liable to cause hemorrage and sometimes cause uncontrollable bleeding. The complex of the present invention can be produced in the form of easily handleable solution simply by mixing a heparin solution with a solution of glycidyl trialkyl ammonium halide. When the solution of the complex is brought into contact with the inner wall of a blood vessel, only the inner surface can be made locally anti-thrombogenetic while keeping the thrombogenetic property of the outer surface of the vessel.
The invention discloses a paclitaxel nanometer preparation and a preparation method and application thereof, wherein the preparation method of the paclitaxel nanometer preparation comprises the steps of mixing paclitaxel, zein and PEG- b Dissolving a PLA amphiphilic block copolymer in an organic solvent, mixing to form a mixed solution serving as a No. 1 stream, using deionized sterile water as a No. 2 stream, injecting the No. 1 stream and the No. 2 stream into a two-channel restricted-area opposite-flushing mixer simultaneously for rapid mixing, and collecting the prepared nanoparticle suspension to obtain a mixture containing the taxol nano preparation. The invention utilizes hydrophobic zein and taxusCompatibility of alcohol, self-assembly property combined with zein and block copolymer PEG- b PLA is taken as a stabilizer coat to prepare the paclitaxel nano particles with improved drug encapsulation efficiency and stability and excellent drug release performance, the method is simple, convenient and quick and is easy to control, and the particle size distribution of the prepared nano particles is uniform.
Patients in the intervention group will receive a defined exercise program twice a week in addition to their usual treatment. Training sessions start immediately after randomization and will be supervised by trained sport students. They will take place twice a week, for twelve weeks in specific training rooms designed to meet the needs of oncological patients in the respective centers. The vibration exercises will take place on a side-alternating vibration platform (GalileoTM, Pforzheim, Germany) ®) according to the previously determined optimal (highest neuromuscular response) setting for each individual. Each session will last for about 15 to 30 minutes, leaving sufficient time for regeneration. Training will consist of four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression. All sessions will be documented by the supervisor.
The invention provides petal water and a preparation method thereof. The petal water is prepared from the following raw materials in weight percentage: 5-50 percent of ciruela extract, 2-20 percent of glycerinum, 1-10 percent of 1,3-butanediol, 0.1-1 percent of carbomer, 0.01-0.1 percent of an anchoic acid derivative, 0.01-0.1 percent of tocopherol, 0.1-1 percent of potassium hydroxide, 0.01-0.5 percent of diazolidinyl urea/iodide, 0.1-0.5 percent of pretreated petal, 0.001-0.5 percent of an essence, 0.1-1 percent of hydrogenated castor oil and the balancing amount of ionized water. The petal water uses a lot of specific wintersweet flower extracts and contains essential oil extracted from wintersweet, so that nutrients can be directly permeate skin to rapidly moisturize skin. The petal water relieves skin tension, darkness, dryness and skin sensitivity in time. After use, the skin color is obviously improved, and the skin is glossy, moistening and retains resiliency. The petal water is suitable for people of any age for daily use or skin first aid.